PortViewPortView
Chiron Real Estate logo

Chiron Real Estate (XRN) Stock Analysis

NYSEReal EstateREIT - Healthcare Facilities

$37.25+0.84%
1-year price historyRange $32.30 – $38.10
52-week range$37.25
$29.05$39.93

What Chiron Real Estate does

Chiron is a real estate investment trust focused on investing in and actively managing critical healthcare infrastructure. With more than a decade of experience as a public company, it has built a diversified portfolio anchored by strong tenants who deliver essential care in their communities nationwide.

Key metrics

Market cap
$493.00M
P/E (TTM)
7.10
EPS (TTM)
$5.24
Beta
1.13
Dividend yield
5.32%
Revenue / share
$11.84
50-day avg
$36.75
200-day avg
$35.31
52-week high
$39.93
52-week low
$29.05
CEO
Mark O. Decker Jr.

ETFs linked to XRN

Broad-market and Real Estate sector ETFs an investor holding Chiron Real Estate is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how XRN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze XRN in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Chiron Real Estate?
Chiron Real Estate trades under the ticker XRN on NYSE.
Which exchange is XRN listed on?
XRN is listed on NYSE.
What sector does Chiron Real Estate operate in?
Chiron Real Estate is classified in the Real Estate sector (REIT - Healthcare Facilities industry).
How can PortView help analyze XRN in a portfolio?
PortView shows XRN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.